Infinity Pharmaceuticals | INFI - Selling And Administration Expenses


Infinity Pharmaceuticals reported $3.75M in Selling and Administration Expenses for its fiscal quarter ending in June of 2023.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.21M 120K Dec/2025
CSL USD 1.23B 498M Dec/2025
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Grifols EUR 320.45M 12.65M Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
Ionis Pharmaceuticals USD 151M 21M Mar/2026
J&J USD 6.03B 719M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Plus Therapeutics USD 3.49M 559K Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
TG Therapeutics USD 73.14M 22.42M Mar/2026